Is Actelion on BDS List?

Boycott

Actelion has to be boycotted

Actelion is a brand of Johnson & Johnson

Invests in Israel and has a long relationship with Isreal.

Proof

Search all brands to boycott

Some other brands to boycott

Unilever

Unilever supports Israeli illegal settlements in occupied Palestine. When Ben & Jerry's, their sub-brand, decided to stop selling its products in Israel, Unilever sold off the Israeli distribution rights to Avi Zinger to circumvent their decision and to force Ben & Jerry's brand name to continue selling in Israel.

Carrefour Mart

Carrefour made huge investments into Israel last year, opening 50 stores and is planning to open a further 100 by 2024.

Osem

Osem is Israels 4th largest food & beverages company (by turnover) after Tnuva, Strauss and Coca-Cola. It has a turnover of $712 million and nearly 5000 employees with 14 factories in Israel.

The Home Depot

Its founder and co-chairman of the Board is an active Zionist. He created the board of directors of Emet, the Pro-Israel Media ‘War Room’ whose function is to ensure that all media in the US stays biased in favor of Israel

Curver

The parent company of Curver operated facilities in the Occupied West Bank's Barkan Industrial Estate. After boycott pressure it seems to have closed the facility, however its history of complicity in the occupation means it should still be boycotted.

Keter

Keter operated facilities in the Occupied West Bank's Barkan Industrial Estate. After boycott pressure it seems to have closed the facility, however its history of complicity in the occupation means it should still be boycotted.

SharkNinja

Founder Mark Rosenzweig has been organizing and contributing to pro Israeli causes, attending IDF events, and also found to be raising funds for an assortment of pro Israeli causes with Sharon Mishkin.

Johnson & Johnson

Invests in Israel and has a long relationship with Isreal

Booking.com

Booking.com allows listings in occupied Palestinian territory, and after announcing it will remove 200 of such listings, it reversed its decision, showing it is knowingly complicit in Israels occupation.

History of Actelion

Actelion, a biopharmaceutical company specializing in innovative treatments for rare diseases, was founded in 1997 in Allschwil, Switzerland, by a team of scientists led by Jean-Paul Clozel, Martine Clozel, and Walter Fischli. The company rapidly established itself as a leader in the field of pulmonary arterial hypertension (PAH) with the development of its flagship drug, Tracleer (bosentan), which was approved by the FDA in 2001. This breakthrough laid the foundation for Actelion’s growth and reputation in the pharmaceutical industry.

Over the next decade, Actelion expanded its product portfolio with several significant therapies, including Opsumit (macitentan) and Uptravi (selexipag), further solidifying its dominance in the PAH market. The company's commitment to addressing unmet medical needs and its innovative research approach attracted the attention of larger pharmaceutical firms. In 2017, Actelion was acquired by Johnson & Johnson for $30 billion, one of the largest deals in the pharmaceutical sector at the time. Post-acquisition, Actelion's research and development unit was spun off into a new entity, Idorsia Ltd, continuing the legacy of innovation with a focus on discovering and developing new therapies.